REGN FY2025 EPS Forecast Cut by Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 5th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $29.37 per share for the year, down from their prior estimate of $38.93. Cantor Fitzgerald currently has a “Neutral” rating and a $1,015.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.75 per share.

REGN has been the subject of several other reports. TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ REGN opened at $710.00 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $78.02 billion, a PE ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08. Regeneron Pharmaceuticals has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock has a fifty day simple moving average of $716.62 and a 200-day simple moving average of $913.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of REGN. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.